Download Library

Download Library

Document Type
Interim Report for the First Nine Months of 2017
Interim Report for the First Nine Months of 2017
A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy – ESGO E-poster – November 2017 (Concin)
A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy – ESGO E-poster – November 2017 (Concin)
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
Genmab First Nine Months of 2017 Results Presentation
Genmab First Nine Months of 2017 Results Presentation
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors
A Phase IIA Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients with Relapsed, Recurrent and / or Metastatic Cervical Cancer - ESMO presentation - September 2017 (Vergote)
A Phase IIA Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients with Relapsed, Recurrent and / or Metastatic Cervical Cancer - ESMO presentation - September 2017 (Vergote)
Investor Presentation, September 2017
Investor Presentation, September 2017
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)
Interim Report for the First Half 2017
Interim Report for the First Half 2017
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors - ESMO abstract - August 2017 (Chenard-Poirier)
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors - ESMO abstract - August 2017 (Chenard-Poirier)
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer - ESMO abstract - August 2017 (Vergote)
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer - ESMO abstract - August 2017 (Vergote)
Genmab First Half 2017 Results Presentation
Genmab First Half 2017 Results Presentation
Q2 2017 Results Podcast
Q2 2017 Results Podcast
First-in-human trial to evaluate safety of HuMax-Axl-ADC in patients with solid tumors - ASCO poster - June 2017 (Lassen)
First-in-human trial to evaluate safety of HuMax-Axl-ADC in patients with solid tumors - ASCO poster - June 2017 (Lassen)
Interim Report for the First Quarter 2017
Interim Report for the First Quarter 2017
10th Kempen & Co. Life Science Conference - April 2017
10th Kempen & Co. Life Science Conference - April 2017
AGM 2017 Presentation
AGM 2017 Presentation
Q1 2017 Results Podcast
Q1 2017 Results Podcast
Genmab Q1 2017 Results Presentation
Genmab Q1 2017 Results Presentation
Election Results of the Annual General Meeting 2017
Election Results of the Annual General Meeting 2017
35th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US - January 2017
35th Annual J.P. Morgan Healthcare Conference, San Francisco, CA, US - January 2017
Full Year 2016 Results Presentation
Full Year 2016 Results Presentation
Corporate Governance Report 2016 - English
Corporate Governance Report 2016 - English
Genmab 2016 Annual Report
Genmab 2016 Annual Report
CSR Report 2016 - English
CSR Report 2016 - English